Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Castration Resistant”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02077634
What this trial is testing

Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

Who this might be right for
Prostate Cancer
Universität des Saarlandes 68
Large-scale testing (Phase 3)Study completedNCT01695135
What this trial is testing

Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

Who this might be right for
Prostate Neoplasms
Janssen Research & Development, LLC 214
Testing effectiveness (Phase 2)Looking for participantsNCT06922318
What this trial is testing

The COSMYC Trial (COmbined Suppression of MYC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 50
Not applicableApproved For MarketingNCT01217697
What this trial is testing

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Who this might be right for
Prostate NeoplasmsGenital Neoplasms, MaleUrogenital Neoplasms+1 more
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Testing effectiveness (Phase 2)WithdrawnNCT01658527
What this trial is testing

TAK-700 in Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Large-scale testing (Phase 3)Study completedNCT03295565
What this trial is testing

Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel

Who this might be right for
Prostate Cancer MetastaticMetastasis
The Netherlands Cancer Institute 100
Testing effectiveness (Phase 2)WithdrawnNCT02906605
What this trial is testing

The Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Testing effectiveness (Phase 2)Looking for participantsNCT07181161
What this trial is testing

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
AstraZeneca 283
Testing effectiveness (Phase 2)Study completedNCT04717154
What this trial is testing

Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Radboud University Medical Center 69
Not applicableStudy completedNCT06204302
What this trial is testing

An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States

Who this might be right for
Non-metastatic Prostate CancerNon-metastatic Castration-resistant Prostate Cancer
Bayer 1,800
Testing effectiveness (Phase 2)UnknownNCT06001255
What this trial is testing

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

Who this might be right for
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Hansoh BioMedical R&D Company 120
Large-scale testing (Phase 3)Looking for participantsNCT03851640
What this trial is testing

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Who this might be right for
MCRPC
Hinova Pharmaceuticals Inc. 417
Testing effectiveness (Phase 2)Looking for participantsNCT05168618
What this trial is testing

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more
University of Utah 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT02893917
What this trial is testing

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Who this might be right for
Advanced Prostate Adenocarcinoma With Neuroendocrine DifferentiationCastration-Resistant Prostate CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation+3 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Active Not RecruitingNCT02051218
What this trial is testing

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Who this might be right for
Metastatic Breast CancerMetastatic Prostate CancerBone Metastases
Swiss Cancer Institute 1,380
Large-scale testing (Phase 3)Not Yet RecruitingNCT07632690
What this trial is testing

QLC5508 in Participants With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Qilu Pharmaceutical Co., Ltd. 700
Testing effectiveness (Phase 2)Study completedNCT01558219
What this trial is testing

Second-line Chemotherapy in Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Tampere University Hospital 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04104893
What this trial is testing

CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
VA Office of Research and Development 40
Testing effectiveness (Phase 2)Study completedNCT03434158
What this trial is testing

Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)

Who this might be right for
Prostate Cancer Metastatic
Spanish Oncology Genito-Urinary Group 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07608718
What this trial is testing

Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Pedro Barata, MD, MSc 19
Next Page
90